From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Cycle
Group
n
Mean
Min
Max
1
Prior Ipi
52
9.9
3
14
No ICB
276
2
49
8.2
252
17
5
12
98
8.6
4
6.7
88
6.6